Slide 1: Insights on clinical practice and ConfIdeS Phase 3 Results
® Insights on clinical practice and ConfIdeS Phase 3 Results Call with distinguished transplant surgeons November 12 2025
Slide 2: Forward-looking statements
Forward-looking statements ® This presentation may contain certain forward-looking statements and forecasts based on our current expectations and beliefs regarding future events and are subject to significant uncertainties and risks since they relate to events and depend on circumstances that will o
Slide 3: Insights on clinical practice and imlifidase Phase 3 Results
Insights on clinical practice and imlifidase Phase 3 Results ® 12 November 2025 Introduction Renée Aguiar-Lucander CEO ConfIdeS Dr. Richard Philipson Topline data Chief Medical Officer Insights on clinical practice Prof. Robert Montgomery Prof. Matthew Cooper Dr. Richard Philipson Q&A Prof. Robert M
Slide 4: Novel, first-in-class IgG-cleaving enzyme from proprietary technology platform
Novel, first-in-class IgG-cleaving enzyme from proprietary technology platform ® What is IgG Hansa’s IgG-cleaving Platform Immunoglobulin G (IgG): a protective antibody Imlifidase – proprietary, first in class IgG cleaving enzyme Transplantation / Gene Therapy: High antibody (IgG) Rapid and ta
Slide 5: Platform is uniquely positioned to treat serious immune mediated diseases
Platform is uniquely positioned to treat serious immune mediated diseases or challenges due to its rapid IgG reduction ® Provides unmatched speed in reducing IgG IgG cleaving enzymes cleave antibodies across all domains Extravascular Cell bound IgG lowering Intravascular IgG IgG IgG modalities Imlif
Slide 6: Addressing Serious Immune Mediated Conditions
Addressing Serious Immune Mediated Conditions ® THERAPEUTIC FOCUS Desensitization Enabling Transplantation Paradigm shift for highly sensitized kidney transplant patients IDEFIRIX® conditionally approved in the EU For desensitization prior to kidney transplantation Enabling Gene Therapy Partnerships
Slide 7: Thousands of highly sensitized U.S. patients face indefinite dialysis
Thousands of highly sensitized U.S. patients face indefinite dialysis ® US Transplant Waitlist ~ 15% of patients are highly sensitized The US represents a significant (cPRA > 80%) market opportunity Significant ~100,000 on the wait list Unmet ~15k highly sensitized ~45,000 patients with Medical Need
Slide 8: ConfIdeS
Insights on clinical practice and imlifidase Phase 3 Results ® 12 November 2025 Introduction Renée Aguiar-Lucander CEO ConfIdeS Dr. Richard Philipson Topline data Chief Medical Officer Insights on clinical practice Prof. Robert Montgomery Prof. Matthew Cooper Dr. Richard Philipson Q&A Prof. Robert M
Slide 9: ConfIdeS
® ConfIdeS An open-label, controlled, randomized Phase 3 trial evaluating 12-month kidney function in highly sensitized (cPRA>99.9%) kidney transplant patients with positive crossmatch against a deceased donor, comparing desensitization using imlifidase with standard of care Renal function in highly
Slide 10: Study Design
® Study Design Imlifidase Organ offer R Pre-screening Screening Delisting of Eligibility unacceptable assessment antigen(s) Control 12 months Imlifidase arm: accept organ offer; if treatment results in xm-conversion from positive to negative, then proceed to transplant Control arm: EITHER accept org
Slide 11: Disposition and Demographics
Disposition and Demographics ® Imlifidase Control Total Disposition n (%) (N=32) (N=32) (N=64) Randomized 32 (100) 32 (100) 64 (100) Treated with imlifidase 30 (93.8) 0 (0) 30 (46.9) Completed study 30 (93.8) 28 (87.5) 58 (90.6) Sex, n (%) Female 18 (56.3) 15 (46.9) 33 (51.6) Male 14 (43.8) 17 (53.1
Slide 12: Efficacy Outcomes
® Efficacy Outcomes Imlifidase Control Imlifidase eGFR Control p-value n n (mean) eGFR (mean) Primary endpoint 32 32 51.5 19.3 <0.0001 eGFR at 12 months in FAS Rank-based non-parametric analysis 32 32 50.0* 0* 0.0001 of eGFR at 12 months eGFR at 12 months in patients transplanted based on organ offe
Slide 13: Safety Outcomes in Imlifidase-Treated Patients
® Safety Outcomes in Imlifidase-Treated Patients • Tolerability of imlifidase was good • There was a low incidence of infusion reactions, and no infusions were interrupted due to an infusion reaction • Infections observed in imlifidase-treated patients were typically not related to treatment • The A
Slide 14: Insights on clinical practice
Insights on clinical practice and imlifidase Phase 3 Results ® 12 November 2025 Introduction Renée Aguiar-Lucander CEO Confides Dr. Richard Philipson Topline data Chief Medical Officer Insights on clinical Prof. Robert Montgomery practice Prof. Matthew Cooper Dr. Richard Philipson Q&A Prof. Robert M
Slide 15: Q&A
Insights on clinical practice and imlifidase Phase 3 Results ® 12 November 2025 Introduction Renée Aguiar-Lucander CEO Confides Dr. Richard Philipson Topline data Chief Medical Officer Insights on clinical practice Prof. Robert Montgomery Prof. Matthew Cooper Dr. Richard Philipson Q&A Prof. Robert M
Slide 16: Close
Insights on clinical practice and imlifidase Phase 3 Results ® 12 November 2025 Introduction Renée Aguiar-Lucander CEO Confides Dr. Richard Philipson Topline data Chief Medical Officer Insights on clinical practice Prof. Robert Montgomery Prof. Matthew Cooper Dr. Richard Philipson Q&A Prof. Robert M
Slide 17: Hansa Biopharma
IZ HAN SAP BIOPHARMA